Diagnostik und Therapie der überaktiven Blase bei der Frau

• Literatur

• 1 Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21: 5-26
• 2 Dmochowski RR, Gomelsky A. Update on the treatment of overactive bladder. Curr Opin Urol 2011; 21: 286-290
• 3 Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br JUrol Int 2001; 87: 760-766
• 4 Kelleher CJ, Cardozo LD, Khullar V et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-1379
• 5 Schafer W, Abrams P, Liao L et al. Good urodynamic practices: uroflowmetriy, filling cystometry and pressure flow studies. Neuro-urol Urodyn 2002; 21: 261-274
• 6 Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity?. J Urol 2006; 175: 191-194 discussion 194–195
• 7 Serati M, Salvatore S, Uccella S et al. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?. Eur Urol 2009; 55: 713-719
• 8 Kagan R, Williams RS, Pan K et al. A randomized, placebo- and active-controlled trial of bazedoxifene / conjugated estrogens for treatment of moderate to severe vulvar / vaginal atrophy in postmenopausal women. Menopause 2010; 17: 281-289
• 9 Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database of systematic Reviews. issue 2006 4.
• 10 Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proceedings (Baylor University Medical Center) 2007; 20/3: 307-314
• 11 De Ridder D, Baert L. Vanilloids and the overactive bladder. Br J Urol Int 2000; 86: 172-180
• 12 Reitz A, Stöhrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-515
• 13 Apostolidis A, Dasgupta P, Denys P et al. European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55: 100-119
• 14 Ozdedeli S, Karapolat H, Akkoc Y. Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled study. Clin Rehabil 2010; 24: 342-351
• 15 Braun PM, Seif C, Scheepe JR et al. Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function. Urologe A 2002; 41: 44-47
• 16 Schmidt RA, Jonas U, Oleson K et al. Sacral nerve stimulation for the treatment of refractory urinary urge incontinence. J Urol 1999; 162: 353-357